AbbVie develops and sells prescription medicines for immunology, neuroscience and oncology, including Skyrizi and Rinvoq. It last closed at $292.78 on Nov 17, down 0.60% on the day. ABBV reports earnings on Wed, Feb 3, 2027. The average 12-month price target from 14 analysts is $321.79 (+9.9% from the last close), with a high of $346.00 and a low of $294.00. Analyst consensus is Strong Buy, based on the latest ratings from 14 firms (12 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 5 whale options trades in ABBV, 20% of them bullish and 80% bearish. In the past 30 days there were 28 dark pool prints totaling $28.6M, the largest $2.4M.
Each firm's latest rating on ABBV in the past 90 days
Average 12-month target
$321.79
▲ 9.9% upside
Based on 14 analysts who set a price target on ABBV in the past 90 days. The average target is $321.79, with a high of $346.00 and a low of $294.00, compared with the last close of $292.78.
Highest target$346.00
Average target$321.79
Lowest target$294.00
Latest rating changes
BarclaysTarget raised
Nov 16Buy$325 → $335
UBSTarget raised
Nov 2Hold$275 → $295
Leerink PartnersMaintained
Nov 2Buy$342
Morgan StanleyTarget raised
Nov 2Buy$310 → $346
GuggenheimTarget raised
Nov 2Buy$288 → $322
Date
Firm
Action
Rating
Price target
Nov 16
Barclays
Target raised
Buy
$325 → $335
Nov 2
UBS
Target raised
Hold
$275 → $295
Nov 2
Leerink Partners
Maintained
Buy
$342
Nov 2
Morgan Stanley
Target raised
Buy
$310 → $346
Nov 2
Guggenheim
Target raised
Buy
$288 → $322
Loading…
Technical Analysis
ABBV · as of the Nov 17 close · updated after every close
Uptrend
The stock is 1% above its 20 day and 5% above its 50 day average. It is 18% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 59). The nearest support is the Pivot at $292.61, and the nearest resistance the Pivot R1 at $294.23.
Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 2.3%/day
Key levels
$302.9352 week high+3.5%
$298.74Swing high (Oct 30)+2.0%
$294.23Pivot R1+0.5%
$292.78Last close
$292.61Pivot−0.1%
$291.17Pivot S1−0.5%
$290.4320 day average−0.8%
$281.23Swing low (Oct 28)−3.9%
$277.1550 day average−5.3%
$265.77100 day average−9.2%
$241.48200 day average−17.5%
$190.7552 week low−34.8%
Indicators
RSI (14)
58.63
Middle of its range
Neutral
MACD
4.79
Below its signal line
Bearish
Stochastic
59.7
Middle of its range
Neutral
ADX (14)
29.8
Trending up
Williams %R
-46.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
42.8
Oversold below −100, overbought above 100
Neutral
Rate of change
+2.4%
Change over 10 sessions
Bullish
ATR (14)
$6.66
Typical daily range, 2.3% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Rising, nearing overbought
Short trendBullish
Long trendNot enough history
MomentumStrong
StretchNear overbought
VolatilityNormal, 4.8%/day
Key levels
$302.9352 week high+3.5%
$298.74Swing high (Oct 30)+2.0%
$294.23Pivot R1+0.5%
$292.78Last close
$292.61Pivot−0.1%
$291.17Pivot S1−0.5%
$290.4320 day average−0.8%
$281.23Swing low (Oct 28)−3.9%
$277.1550 day average−5.3%
$265.77100 day average−9.2%
$241.48200 day average−17.5%
$190.7552 week low−34.8%
Indicators
RSI (14)
69.66
Strong, overbought above 70
Neutral
MACD
16.23
Above its signal line
Bullish
Stochastic
83.2
Near the top of its range
Overbought
ADX (14)
36.2
Trending up
Williams %R
-18.1
Oversold below −80, overbought above −20
Overbought
CCI (20)
130.2
Oversold below −100, overbought above 100
Overbought
Rate of change
+13.9%
Change over 10 sessions
Bullish
ATR (14)
$14.07
Typical daily range, 4.8% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200–
What happened before, for ABBV
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ABBV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Whale flow leans bearish1 bullish and 4 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow ABBV usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ABBV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.
From the company's 10-Q filed Nov 3, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABBV is in one of them and how their past ABBV trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About AbbVie
AbbVie is a biopharmaceutical company based in North Chicago, Illinois. It researches, develops, manufactures and sells prescription medicines in immunology, neuroscience and oncology, including Skyrizi, Rinvoq and Botox Therapeutic. Its treatments are used by patients with autoimmune diseases, migraine, Parkinson's disease and several blood cancers. The company sells its products in many countries around the world.